HPS-034 - Real-world effectiveness of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in a specialised tertiary hospital in Kuwait: A retrospective cohort study

• At: Copenhagen (Denmark) (2025)
• Type: Poster
• Poster code: HPS-034
• By: ALSAFFAR, Noor (University Of Strathclyde, United Kingdom)
• Co-author(s): Dr Noor Alsaffar (University Of Strathclyde, Glasgow, United Kingdom)
  Dr. Marion Bennie (University Of Strathclyde, Glasgow, United Kingdom)
  Dr. Amanj Kurdi (University Of Strathclyde, Glasgow, United Kingdom)
  Dr. Maryam Alowayesh (College of Pharmacy, Kuwait University, Kuwait)
  
• Abstract:

  Introduction: Statins are the cornerstone therapy for managing uncontrolled low-density lipoprotein cholesterol (LDL-C), with ezetimibe as an add-on for insufficient control. In 2016, proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9Is) were introduced in Kuwait for patients with persistent lipid control issues. This study aimed to..

The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress. Please login